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Background: The purpose of this study is to investigate the prognostic factors of stereotactic radiotherapy for
stage I NSCLC to improve outcomes.
Methods: Stage I non-small cell lung cancer patients who were treated with stereotactic radiotherapy between
2005 and 2009 at our hospital were enrolled in this study. The primary endpoint was local control rate. Survival
estimates were calculated from the completion date of radiotherapy using the Kaplan-Meier method. The
prognostic factors including patients’ characteristics and dose-volume histogram parameters were evaluated using
Cox’s proportional hazard regression model.
Results: Eighty patients (81 lesions) treated with 3 dose levels, 48 Gy/4 fractions, 60 Gy/8 fractions and 60 Gy/15
fractions, were enrolled in this study. Median follow-up was 30.4 months (range, 0.3 – 78.5 months). A Cox
regression model showed T factor (p = 0.013), biological effective dose calculated from prescribed dose (BED10)
(p = 0.048), and minimum dose for PTV (p = 0.013) to be prognostic factors for local control. Three-year overall
survival rate and local control rate were 89.9% (T1: 86.8%, T2: 100%) and 89.0% (T1: 97.9%; T2: 64.8%), respectively.
When the 3-year local control rates were examined by prescribed doses, they were 100% for the dose per fraction
of 48 Gy /4 fractions (105.6 Gy BED10), 82.1% for 60 Gy/8 fractions (105 Gy BED10), and 57.1% for 60 Gy/15 fractions
(84 Gy BED10). The median value of the minimum dose for PTV (%) was 89.88 (%), and the 3-year local control
rates were 100% in those with the minimum dose for PTV (%) ≥ 89.88% and 79.2% in those with the minimum
dose for PTV (%) < 89.88%.
Conclusions: Our results suggest that T factor, BED10, and minimum dose for PTV influence the local control rate.
Local control rate can be improved by securing the minimum dose for PTV.
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PTV marginBackground
In stereotactic radiotherapy for lung tumors, the dose at
the lesion has been successfully increased through ad-
vancement of irradiation devices, improvement of set-up
accuracy, introduction of image-guidance technology
and measures for respiratory tumor movement [1,2]* Correspondence: guldoktu@gmail.com
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reproduction in any medium, provided the orwhile ensuring a high level of safety. For stage I non-
small cell lung cancer (NSCLC), in particular, some
reports suggest that short-term outcomes of stereotactic
radiotherapy are comparable to those of surgeries [3,4].
Furthermore, patients diagnosed with lung cancer in the
early stage have increased recently due to the use of
computed tomography (CT) scans and educational cam-
paigns for cancer screening [5,6].
However, lung cancer is still the main cause of cancer
death worldwide, and local recurrence after stereotactic
radiotherapy is not rare [3,7-9]. The purpose of thisLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Treatment factor
Computed
tomography
- Long time scan




-Algorithm: Pencil beam convolution
- Heterogeneity correction: Modified Batho
Power Law
Targeting - Observation of the tumor by fluoroscopy
in advance
- GTV + 0–5 mm = CTV, CTV + 5–10 mm =
PTV
Irradiation field - non-coplanar multi-dynamic arcs and/or
multi-static beams
Prescription - 48 Gy/4 fractions, 60 Gy/8 fractions,
60 Gy/15 fractions
- Prescription for the iso-center
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We reviewed data for all of the 80 patients (81 lesions)
with stage I NSCLC who had undergone stereotactic
radiotherapy in our hospital between March 2005 and
July 2009. All patients included in this study had histo-
logical or cytological diagnosis of NSCLC and were
staged as Union Internationale Contre le Cancer
(UICC)-6 stage IA or IB by the use of CT. If available,
18 F-fluorodeoxyglucose positron emission tomography
(FDG-PET) was used for staging. They either had a
medical contraindication to surgery or refused surgery.
Patient eligibility was not restricted on the basis of
tumor location, unless a part of the esophagus, heart,
main bronchi, hilus, spinal cord, or skin would be
exposed to high-dose radiation. If the treatment plan
included these organs in the high-dose areas, the
patients were treated with conventional radiotherapy or
modified stereotactic radiotherapy with a moderate ir-
radiation dose; those patients were excluded from this
study.
The primary endpoint was local recurrence. The sec-
ondary endpoint was overall survival. Patients’ back-
ground factors, various clinical parameters, and clinical
course after irradiation were surveyed using information
sources including medical records, data saved at the prac-
tice support terminal of our hospital, case follow-up cards
of our department, and irradiation records. Local recur-
rence was defined as local progression that was 1.5 times
or more the dimensions of original tumor [10]. Tumors
were observed on CT and/or 18 F-fluorodeoxyglucose
positron emission tomography (FDG-PET) in order to
assess the primary tumor’s stage and the presence or
absence of recurrence. If FDG-PET was available, the
maximum standardized uptake value (SUVmax) greater
than 5.0 was considered as recurrence [11]. The physi-
cians and radiation oncologists finally decided to be local
recurrence.
The study protocol was approved by the Ethical Com-
mittee of our institution, and informed consent was
obtained from all patients.
Radiotherapy
Treatment factor is summarized in Table 1. To deter-
mine the extent of tumor movement due to respiration
and establish an individual internal margin, all patients
were placed in a simulator for fluoroscopic examination
just prior to CT scanning for treatment planning in the
exact same position. Serial CT scans were performed at
intervals of 2.5 mm. A CT scan with an acquisition timeof 4 seconds that included internal motion was per-
formed to define the internal margin accurately.
Patients were immobilized in the supine position with
an individually fashioned half-body vacuum cast. Both
the upper extremities were immobilized in the raised
position unless the tumor was located at the apex of the
lung, in which case both the upper extremities were
immobilized beside the body.
Gross tumor volume (GTV) was defined as the visible
extent of the tumor on the CT image at the lung win-
dow. Clinical target volume (CTV) was defined as GTV
plus 0–5 mm margin for microscopic invasion. Internal
target volume (ITV) was set equal to CTV because CT
scanning was performed with an acquisition time of 4
seconds, and we consider that long-time (4 seconds)
scan CT depicted virtually the entire tumor trajectory
[12]. Planning target volume (PTV) was determined by
allowing for a set-up margin of 5 - 10mm beyond the
ITV.
Treatment planning was performed with non-coplanar
multi-dynamic arcs and/or multi-static beams by using a
three-dimensional radiotherapy treatment planning sys-
tem (Eclipse, Varian Medical Systems, Palo Alto, CA).
The algorithm to calculate the dose was pencil beam
convolution (PBC). Modified Batho Power law correc-
tion was used as the tissue heterogeneity correction al-
gorithm. The target reference point was defined as the
center of the PTV, and the dose was prescribed for its
point. PTV was encompassed by the minimum 90% dose
line of the reference point dose as possible. X-rays of 6
MV were used in all treatments.
The treatment took place using Clinac 23EX, Varian
Medical Systems, Palo Alto, CA. In each irradiation, the
Table 2 Patient backgrounds
Age median, 77 years (range: 54–90 years)
Sex Male: 64 lesions, 64 patients
Female: 17 lesions, 16 patients
Histopathology Adenocarcinoma: 33 patients
Squamous cell carcinoma: 22 patients
Large cell carcinoma: 5 patients
Unclassified: 20 patients
Stage T1 (Stage IA): 63 lesions
T2 (Stage IB): 18 lesions
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and set-up and/or inter-fractional errors were corrected.
The patients were treated with a radiation schedule
of 12 Gy /fraction ×4 fractions (48 Gy/4 fractions),
7.5 Gy/fraction ×8 fractions (60 Gy/8 fractions), and
4 Gy/fraction ×15 fractions (60 Gy/15 fractions). When
the tumor was close to a risk organ, 7.5 Gy/fraction ×8 frac-
tions or 4 Gy/fraction ×15 fractions was used to reduce the
risk of serious toxicity due to set-up error or internal
motion.
Follow-up
The first examination, including a clinical examination
and CT scanning, was performed 4–6 weeks after treat-
ment to assess the pulmonary reaction. Thereafter, the
patients underwent follow-up examinations every 3–6
months for 2 years following treatment. After 2 years,
follow-up examinations were performed every 6 months.
Statistical analysis
The prognostic factors for local control, including age,
sex, T factor, histology, planning target volume (PTV),
minimum dose for PTV (%), biological effective dose
(BED) calculated from prescribed dose (BED10), and bio-
logical effective dose calculated from minimum dose
(BEDmin), were investigated by stepwise Cox’s propor-
tional hazard regression model for multivariate analysis.
Hazard ratio for continuous data was evaluated with
Wald χ2 test statistics. Sex and T factor were considered
as categorical data. To investigate for the presence of
multicollinearity, correlation coefficients were calculated
for all variables. The hazard ratio was observed graphic-
ally to check its constancy.
BED10 and BEDmin were calculated using the linear
quadratic formula in order to compare the effects of
treatments with different fraction sizes and total doses.
BED was given by: BED= nd[1 + d/(α/β)], where n is the
number of fractions, d is the dose/fraction, and α/β ratio
is 10 Gy. BED was not corrected with values for overall
radiation time or tumor doubling time.
Overall survival, cause specific, and local control rates
were calculated using the Kaplan-Meier method and
statistical differences were evaluated by the log-rank test.
When a continuous data was used as a variable for the
Kaplan-Meier method, the data was divided by the me-
dian value into two groups. Statistical significance was
defined as a value of p<0.05 in the present study. All
analyses were performed using the SPSS 17.0 software
package (SPSS Inc, Chicago, IL).
Results
Patients
All eighty patients were enrolled in the present study. The
patients’ characteristics are shown in Table 2. There were64 men (64 lesions) and 16 women (17 lesions) with ages
ranging from 54 to 90 years (median, 70 years). All of the
patients completed the treatment without acute adverse
effects. The observation periods from the time of comple-
tion of stereotactic radiotherapy ranged from 0.3 to 78.5
months with a median of 30.4 months. The patients’ histol-
ogies were adenocarcinoma (33 patients), squamous cell
carcinoma (22 patients), large cell carcinoma (5 patients),
and unclassified NSCLC (20 patients). Sixty-three tumors
were T1 (Stage IA) masses and 18 tumors were T2 (Stage
IB). Performance status (PS) of the patient was 0–2.
Fifteen (18.8%) of the 80 patients showed evidence of
recurrence. Local, regional (nodal) and distant recur-
rences were observed in 6 patients (7.5%), 3 patients
(3.8%) and 12 patients (15%), respectively. Time to local
failure varied between 12.2 and 33.7 months (median,
18.1 months).
Four patients died of NSCLC treated with stereotactic
radiotherapy and 6 patients died of intercurrent causes.
The 4 patients who died of NSCLC treated with stereo-
tactic radiotherapy included 1 patient with local disease
and regional lymph node metastasis and 3 patients with
distant metastases. Intercurrent causes were colorectal
cancer, aspiration pneumonia, advanced esophageal can-
cer, renal failure, chronic obstructive pulmonary disease
(COPD), and multiple liver metastases considered to be
from another site of NSCLC.
Radiotherapy
We treated 45 patients with a radiation schedule of
12 Gy /fraction ×4 fractions, 29 patients with a schedule
of 7.5 Gy/fraction ×8 fractions and 7 patients with a
schedule of 4 Gy/fraction ×15 fractions. We treated the
tumor in consecutive weekdays.
Statistical analysis
The results of multivariate analysis showed significant
differences in T factor, BED10 and minimum dose for
PTV (%). The hazard ratios were 0.027, 0.383 and 0.731,
respectively (Table 3). Namely, the hazard ratio of T1
was 0.027 on defining the hazard ratio of T2 as 1.0. In
Figure 2 Local control rate by BED10. The 3-year local control
rates were 100% in treatment with 105.6 Gy BED10 (48 Gy/4
fractions), 82.1% in treatment with 105.0 Gy BED10 (60 Gy/8 fractions)
and 57.1% in treatment with 84.0 Gy BED10 (60 Gy/15 fractions).
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crease was 0.731 for local recurrence. In BED10 (Gy), the
hazard ratio for each 10 Gy increase was 0.383. Wald χ2
test indicated that minimum dose for PTV (%) was the
strongest prognostic factor among these variables. There
was no multicollinearity problem in this study. We
observed constant hazard ratio graphically.
The 3-year local control rates were 89.0% (95% confi-
dence interval [CI], 80.4% – 97.6%) in all patients, 97.9%
(95% CI, 93.8% – 102.0%) in those with T1 tumors and
64.8% (95% CI, 38.9% – 90.7%) in those with T2 tumors.
The log-rank test showed a significant difference be-
tween these two groups (p = 0.001, Figure 1). When the
3-year local control rates were examined by prescribed
doses, they were 100% for the dose per fraction of 12 Gy
/fraction ×4 fractions (105.6 Gy BED10), 82.1% (95% CI,
63.1% – 101.1%) for 7.5 Gy/fraction ×8 fractions
(105 Gy BED10), and 57.1% (95% CI, 20.4% – 93.8%) for
4 Gy/fraction ×15 fractions (84 Gy BED10) with a signifi-
cant difference (p = 0.001, Figure 2). The median value
of the minimum dose for PTV (%) was 89.88 (%), and
the 3-year local control rates were 100% in those with
the minimum dose for PTV (%) ≥ 89.88% and 79.2%
(95% CI, 63.9% – 94.5%) in those with the minimum
dose for PTV (%) < 89.88%. The log-rank test showed a
significant difference between these two groups (p =
0.016, Figure 3).Figure 1 Local control rates of T1 and T2 tumors treated with
stereotactic radiotherapy. The 3-year local control rates were
97.9% in patients with T1 tumors and 64.8% in those with
T2 tumors.The 3-year overall survival rate for all patients was
89.9% (95% CI, 81.9% – 97.9%). The 3-year overall sur-
vival rates were 86.8% (95% CI, 76.6% – 97.0%) in
patients with T1 tumors and 100% in those with T2
tumors. No significant difference was observed between
these two groups (log-rank test, p = 0.29). The 3-year
cause specific survival rate was 97.0% (95% confidence
interval, 92.9% - 101.1%).
Discussion
Multivariate analysis indicated that T factor, BED10, and
minimum dose for PTV (%) influence local control.
Among these, BED and minimum dose for PTV (%) can
be changed by artificial intervention. BED10 would de-
pend on the dose per fraction and total dose at a dose
prescription, and they are generally determined by
patient’s factor including tumor location, size, and
patient’s general condition. The minimum dose for PTV
(%) is decided by the radiotherapy plan including a tar-
geting, margin factor, respiratory gating technique, and
tumor tracking method. The results of this study suggest
that the local control rate after stereotactic radiotherapy
for stage I NSCLC can be improved by securing the
minimum dose for PTV (%) when radiation oncologists
produce a radiotherapy plan.
Prognostic factors
Onimaru et al. analyzed 41 patients with stage I NSCLC
treated by stereotactic radiotherapy and reported that T
factor and prescribed dose were significant factors for

















0.731 6.203 0.571 – 0.935 0.013
BED10 (Gy) [Unit:
10 Gy]
0.383 3.898 0.148 – 0.993 0.048
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was not a significant factor in spite of the fact that it was
used as a variable [2]. Probable reasons were the hetero-
geneity of the patients and the confounding factors ana-
lyzed in their study. Patients in whom a narrow margin
was used included 7 patients with a T1 tumor and 3
patients with a T2 tumor.
In contrast, another study showed that tumor diameter
and gender were the most significant factors affecting
outcomes after stereotactic radiotherapy in recursive
partitioning analysis; for comparison, tumor diameter
was the only significant factor for local progression in a
Cox proportional hazards model, and no margin-related
variable was used [13]. This was possibly because of the
female pathological inclination to have adenocarcinoma.
Some reports suggest that adenocarcinoma patients with
stage I NSCLC tend to have a better survival [14]. SinceFigure 3 Local control rate by the minimum dose for PTV (%).
The 3-year local control rates were 100% in those with the
minimum dose for PTV (%) ≥ 89.88% and 79.2% (95% CI,
63.9% – 94.5%) in those with the minimum dose for PTV (%) < 89.88%.
89.88% is the median value of the minimum dose for PTV (%).only 16 (20%) of the patients in our study were females,
it was difficult to determine whether female gender is a
significant prognostic factor.
Small sample size and retrospective protocol limit fur-
ther interpretation of such findings, while tumor size is
regarded as an independent prognostic factor for stage I
NSCLC patients in general [14]. Multi-institutional
phase II trials are currently be conducted by the Radi-
ation Therapy Oncology Group (Protocol 0236) and
Japan Clinical Oncology Group (Protocol 0403). Results
of detailed statistical analysis of data obtained in these
trials are awaited to clarify various issues including
issues discussed below.
T factor
This study also showed that T factor is the most signifi-
cant factor affecting local control after stereotactic
radiotherapy for stage I NSCLC. Several studies have
shown that local recurrence is more frequent for larger
GTVs [2,3,15] and that tumor size is an independent
prognostic factor for stage I NSCLC patients [14]. A lar-
ger tumor tends to have hypoxic cells and cancer stem
cells, which are more aggressive and resistant to radio-
therapy [16], and a larger tumor would therefore have
more time to metastasize than a smaller one. Cancer
stem cells are recognized as a source of local or distant
relapse [17]. A tendency to decrease the dose in the
tumor periphery would also exacerbate the situation. In
this study, the minimum dose for PTV (%) tended to be
slightly lower for larger PTV (Figure 4). In addition,
66.7% of the patients with a T2 tumor and 38% of the
patients with a T1 tumor were prescribed 7.5 Gy/frac-
tion ×8 fractions (105 Gy BED10) or 4 Gy/fraction ×15
fractions (84 Gy BED10). Hence, T2 tumors tended to be
treated with longer overall radiation time than did T1
tumors.
Figure 1 shows that there was a significant difference
between local control rates in patients with T1 and T2
tumor. There was a decline in local recurrence and a
plateau at about three years with no local recurrence
after that period, although late recurrences at 5 years or
more have been reported [18]. Local control in our hos-
pital was almost same as several reports (Table 4). The
3-year survival rate in our study was better than that in
other studies. It might be due to good collaboration with
other departments and/or other hospitals, that is, not
only death of primary tumor but also death of other
causes more fewer than previously, because three-year
cause specific survival rate was 97.0 (%), and it was al-
most same as some reports [19]. Relatively good survival
rate could also imply that additional treatments after re-
lapse including chemotherapy, re-irradiation, and best
supportive care can influence survival. In addition, oper-
ability and PS may have affected the results of survival.
Figure 4 Correlation of Minimum dose for PTV (%) and PTV. Minimum dose for PTV (%) tended to be slightly lower for larger PTV.
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When two types of prescriptions, one with BED10 of
105.6 Gy and the other with BED10 of 105 Gy, were
compared, local control rates differed markedly despite
only a slight difference in BED10 (Figure 2).
BED calculated by the linear quadratic formula with
no correction was used in this study. The factor of over-
all radiation time was therefore not taken into account.
During prolonged radiation delivery, sublethal damage
repair takes place, leading to a decreased effect of radi-
ation [20]. Actually, there was no local recurrence in
patients with the shortest radiotherapy (105.6 Gy BED10)
in this study, although 6 patients treated with 105.6 Gy
BED10 had a T2 tumor.
Many clinicians often use the linear-quadratic (LQ)
model and BED to estimate the effects of various radi-
ation schedules, but it has been suggested that the LQ
model is not applicable to stereotactic radiotherapy be-
cause of its high dose per fraction [20]. By contrast,
Fowler et al. reported that the LQ model fitted the radi-










Timmerman [6] 55 60 20 18
Nagata [5]* 42 48 12 10
Fakiris [7] 70 60, 66 20, 22 18
Onishi [3]* 257 18 - 75 4.4 - 35 57
Our results* 80 48 - 60 4 – 12 84
BED10 is biological effective dose (BED) calculated from prescribed dose.
* Dose is calculated at the iso-center.
**Local control (%) = (number of patients without local recurrence) / (number of allThe best-fit model for tumor responses to stereotactic
radiotherapy warrants further research.
Furthermore, we speculate that restriction of pre-
scribed doses due to the vicinity of central structures
and/or the radiation oncologist’s discretion in consider-
ation of factors including performance status affected
the control rate, resulting in this difference (Figure 2).
Some reports have shown that local control rate with
over 100 Gy BED10 was higher than that with less than
100 Gy BED10 [3], although a meta-analysis conducted
by Zhang et al. showed no significant difference between
BED10 < 100 Gy and BED10 ≥ 100 Gy [21]. Medium
BED or medium to high BED were recommended by
Zhang et al. In our study, 4 Gy/fraction ×15 fractions
(84 Gy BED10) was suggested to be insufficient for treat-
ment of stage I NSCLC, particular in patients with a T2
tumor.
Further studies are needed to clarify the optimal
total dose and fractions and the risk factors for
relapse and side effects. When lower BED has to be
prescribed because of tumor size, location of the tumor,mall cell lung cancer






0 34.4 98.2 55.8
5.6 30 97.8 83
0 - 211.2 50.2 94.3 42.7
.6 - 180 38 88.7 56.8
– 105.6 30.4 92.5 89.9
patients)×100.
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considered [22].
Minimum dose for PTV (%)
Wald χ2 test indicated that minimum dose for PTV (%)
was the strongest prognostic factor. We carried out the
calculation of the local control, grouping by the mini-
mum dose for PTV (%) into 2 groups: the minimum
dose for PTV (%) ≥ 89.88% and < 89.88%, and there was
significant difference. Baumann et al. showed by univari-
ate analysis that radiation dose calculated in equivalent
doses in 2 Gy fractions (EQD2) at the periphery of the
PTV had an impact on survival but not on local recur-
rence rate [15]. A trend toward smaller PTV margins for
recurrent patients was also observed in their phase II
trial [23]. Among multiple factors, BED at the PTV mar-
gin was found to be the only significant factor influen-
cing local control by Wulf et al. [24].
BED at the PTV margin can decrease for many rea-
sons. The internal margin is not constant in each frac-
tion, and sufficient management of the respiration factor
is therefore important for planning particularly in the
lower lobe. Dosimetric problems also arise from the lim-
ited accuracy of dose calculation algorithms in treatment
planning systems. Lax et al. reported that the pencil
beam algorithm significantly overestimates the dose [25].
Radiation oncologists must have knowledge of the char-
acteristics of the algorithm used in each institution.
According to some reports, irradiation for large volumes
of the lung can result in high-grade radiation pneumon-
itis [26]. Radiation pneumonitis is the most important
adverse reaction in stereotactic radiotherapy for a lung
tumor and its prevention is a crucial task because of its
severity. For this reason, the leaf margin might be
reduced at the discretion of the radiation oncologist
when the target is large and/or the patient has respira-
tory complications.
Efforts to avoid unnecessary reduction of the margin
should be made. Nowadays, we use the dose prescribed
by 95% of the PTV (D95) for the stereotactic radiother-
apy. We will conduct further research to determine an
acceptable minimum dose (%).
The continuing development of technologies including
respiratory gated radiotherapy and real-time tumor
tracking should enable further reduction of the margin
for PTV. Therefore, further dose escalation for a larger
tumor such as a T2 tumor may be possible, and severe
side effects may be reduced since the amount of normal
tissue irradiation will also be reduced with reduction of
the margin for PTV.
Conclusion
T factor, BED10, and minimum dose for PTV (%) influence
the local control rate. Local control rates can be improvedby securing the minimum dose for PTV when radiation
oncologists produce a radiotherapy plan for stage I non-
small cell lung cancer in stereotactic radiotherapy.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
KJ and MK conceived of the study. YS and MK participated in data collection.
YS performed the statistical analysis and drafted the manuscript. KJ, MK, KT,
and NK helped to draft the manuscript. KJ, TS, and HM critically reviewed the
article. All authors read and approved the final manuscript.
Author details
1Department of Radiation Oncology, Tohoku University School of Medicine,
Sendai, Japan. 2Research Center for Charged Particle Therapy, National
Institute of Radiological Sciences, Chiba, Japan. 3Department of Therapeutic
Radiology, Clinical Radiological Science, Course of Radiological Technology,
Tohoku University School of Health Sciences, Sendai, Japan. 4Department of
Radiation Oncology, Tohoku University School of Medicine, 1-1 Seiryo-chou,
Aoba-ku, Sendai 980-8574, Japan.
Received: 13 July 2012 Accepted: 26 October 2012
Published: 31 October 2012
References
1. Buyyounouski MK, Balter P, Lewis B, et al: Stereotactic body radiotherapy
for early-stage non-small-cell lung cancer: report of the ASTRO emerging
technology committee. Int J Radiat Oncol Biol Phys 2010, 78:3–10.
2. Onimaru R, Fujino M, Yamazaki K, et al: Steep dose–response relationship
for stage I non-small-cell lung cancer using hypofractionated high-dose
irradiation by real-time tumor-tracking radiotherapy. Int J Radiat Oncol
Biol Phys 2008, 70:374–381.
3. Onishi H, Shirato H, Nagata Y, et al: Hypofractionated Stereotactic
Radiotherapy (HypoFXSRT) for Stage I Non-small cell lung cancer:
Updated results of 257 patients in a Japanese multi-institutional study.
J Thorac Oncol 2007, 2:S94–S100.
4. Asamura H, Goya T, Koshiishi Y, et al: A Japanese Lung Cancer Registry
Study: Prognosis of 13010 Resected Lung Cancers. J Thorac Oncol 2007,
3:46–52.
5. Willard AF, Jerri LP, Herman RM: Ten-year survey of lung cancer treatment
and survival in hospitals in the United States. A national cancer data
base report. Cancer 1999, 86(9):1867–1876.
6. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berq
CD, Black WC, Clapp JD, Faqerstrom RM, Gareen IF, Gatsonis C, Marcus PM,
Sicks JD: Reduced lung-cancer mortality with low-dose computed
tomographic screening. N Engl J Med 2011, 365(5):395–409.
7. Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T,
Sakamoto M, Mitsumori M, Shibuya K, Araki N, Yano S, Hiraoka M:
Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body
radiotherapy in 4 fractions for primary lung cancer using a stereotactic
body frame. Int J Radiat Oncol Biol Phys 2005, 63(5):1427–1431.
8. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A,
Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H: Stereotactic
body radiation therapy for inoperable early stage lung cancer.
JAMA 2010, 303(11):1070–1076.
9. Fakiris AJ, McGarry RC, Yiannoutsos CT, Papiez L, Williams M, Henderson MA,
Timmerman R: Stereotactic body radiation therapy for early-stage
non-small-cell lung carcinoma: four-year results of a prospective phase II
study. Int J Radiat Oncol Biol Phys 2009, 75(3):677–682.
10. Koto M, Takai Y, Ogawa Y, Matsushita H, Takeda K, Takahashi C, Britton KR,
Jingu K, Takai K, Mitsuya M, Nemoto K, Yamada S: A phase II study on
stereotactic body radiotherapy for stage I non-small cell lung cancer.
Raditother Oncol 2007, 85(3):429–434.
11. Shiono S, Abiko M, Sato T: Positron emission tomography/computed
tomography and lymphovascular invasion predict recurrence in stage I
lung cancers. J Thorac Oncol 2010, 6:43–47.
12. Takeda A, Kunieda E, Shigematsu N, Hossain DM, Kawase T, Ohashi T,
Fukada J, Kawaguchi O, Uematsu M, Takeda T, Takemasa K, Takahashi T,
Kubo A: Small lung tumors: long-scan -time CT for planning of
Shirata et al. Radiation Oncology 2012, 7:182 Page 8 of 8
http://www.ro-journal.com/content/7/1/182hypofractionated stereotactic radiation therapy-initial findings.
Radiology 2005, 237:295–300.
13. Matsuo Y, Shibuya K, Nagata Y, Takayama K, Norihisa Y, Mizowaki T,
Narabayashi M, Sakanaka K, Hiraoka M: Prognostic factors in stereotactic
body radiotherapy for non-small –cell lung cancer. Int J Radiat Oncol Biol
Phys 2011, 79:1104–1111.
14. Koike T, Tsuchiya R, Goya T, Sohara Y, Miyaoka E: Prognostic factors in 3315
Completely Resected Cases of Clinical Stage I Non-small Cell Lung
Cancer in Japan. J Thorac Oncol 2007, 2:408–413.
15. Baumann P, Nyman J, Lax I, Friesland S, Hoyer M, Ericsson SR, Johansson KA,
Ekberg L, Morhed E, Paludan M, Wittgren L, Blomgren H, Lewensohn R:
Factors important for efficacy of stereotactic body radiotherapy of
medically inoperable stage I lung cancer. A retrospective analysis of
patients treated in the Nordic countries. Acta Oncol 2006, 45:787–795.
16. Fowler JF, Tomé WA, Fenwick JD, Mehta MP: A challenge to traditional
radiation oncology. Int J Radiat Oncol Biol Phys 2004, 60:1241–1256.
17. Brunner TB, Kunz-Schughart LA, Grosse-Gehling P, Baumann M:
Cancer Stem Cells as a Predictive Factor in Radiotherapy. Semin Radiat
Oncol 2012, 22:151–174.
18. Matsuo Y, Shibuya K, Nagata Y, Norihisa Y, Narabayashi M, Sakanaka K,
Ueki N, Mizowaki T, Hiraoka M: Preliminary Report of Late Recurrences,
at 5 Years or more, after Stereotactic Body Radiation Therapy for
Non-small Cell Lung Cancer. J Thorac Oncol 2012, 7:453–456.
19. Baba F, Shibamoto Y, Ogino H, Murata R, Sugie C, Iwata H, Otsuka S,
Kosaki K, Nagai A, Murai T, Miyakawa A: Clinical outcomes of stereotactic
body radiotherapy for stage I non-small cell lung cancer using different
doses depending on tumor size. Radiat Oncol 2010, 5(81):1–7.
20. Shibamoto Y, Otsuka S, Iwata H, Sugie C, Ogino H, Tomita N:
Radiobiological Evaluation of the Radiation Dose as Used in
High-precision Radiotherapy: Effect of Prolonged Delivery Time and
Applicability of the Linear-quadratic Model. J Radiat Res 2012, 53:1–9.
21. Zhang J, Yang F, Li B, Li H, Liu J, Huang W, Wang D, Yi Y, Wang J:
Which is the optimal biological effective dose of stereotactic body
radiotherapy for stage I non-small-cell lung cancer? A meta-analysis.
Int J Radiat Oncol Biol Phys 2011, 81:e305–e316.
22. Chi A, Liao Z, Nguyen NP, Xu J, Stea B, Komaki R: Systemic review of the
patterns of failure following stereotactic body radiation therapy in
early-stage non-small-cell lung cancer: Clinical implications. Radiat Oncol
2010, 94:1–11.
23. Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, Drugge N,
Ekberg L, Friesland S, Johansson KA, Lund JÅ, Morhed E, Nilsson K, Levin N,
Paludan M, Sederholm C, Traberg A, Wittgren L, Lewensohn R: Outcome in
a Prospective Phase II Trial of Medically Inoperable Stage I Non-Small
Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy.
J Clin Oncol 2009, 27:3290–3296.
24. Wulf J, Baier K, Mueller G, Flentje MP: Dose–response in stereotactic
irradiation of lung tumors. Radiat Oncol 2005, 77:83–87.
25. Lax I, Panettieri V, Berit W, et al: Dose-distributions in SBRT of lung tumors:
Comparison between two different treatment planning algorithms and
Monte-Carlo simulation including breathing motions. Acta Oncol 2006,
45:978–988.
26. Yamashita H, Nakagawa K, Nakamura N, Duch MA, Näslund I, Baumann P,
Gagliard G: Exceptionally high incidence of symptomatic grade 2–5
radiation pneumonitis after stereotactic radiation therapy for lung
tumors. Radiat Oncol 2007, 2:1–11.
doi:10.1186/1748-717X-7-182
Cite this article as: Shirata et al.: Prognostic factors for local control of
stage I non-small cell lung cancer in stereotactic radiotherapy: a
retrospective analysis. Radiation Oncology 2012 7:182.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
